Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis
So where harm can happen is not having that whole system, that ecosystem, you know, approach for an individual on the flip side, where it can be so incredibly helpful
February 2024: In February 2024, the United States Judicial Panel on Multidistrict Litigation (MDL Panel), agreed to consolidate lawsuits involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including Trulicity
Since the trial failed, the company also announced that theyre halting the one-year open label extension trial period, where all participants including those who initially received the placebo, would have the opportunity to take the drug